June 24, 2022
MOU Op Ed: FDA is in a hole. It should stop digging.
An opinion piece by APC’s Scott Brunner, published this week in Pharmacy Times, argues that the FDA ought to abandon the MOU on interstate shipments of compounded medications “because the specific problem the MOU was conceived in 1997 to address no longer exists.” Instead, Brunner writes,
“…The FDA should join with the compounding profession to change the law. Eliminate that out-of-date MOU requirement—an MOU that several states have already said they can’t sign (because of state law) or won’t sign (because of the administrative burden). In its place create a statutory regime for reporting shipping info to state boards of pharmacy, to be shared with FDA.”